Session Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis
Session Type: Poster Session (Sunday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim was to investigate the differences between SLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS).
Methods: Patients from the RELESSER-T registry were included. RELESSER-T is a multicenter, hospital-based registry, with retrospective cross-sectional collection of data from a large representative sample of adult non-selected patients with SLE attending Spanish rheumatology services from the public national health system.
Results: We included 3651 SLE patients and 1368 were positive for aPL. Overall 2283 patients were classified as SLE no aPL, 552 as SLE-APS and 816 as SLE-aPL. Demographic data, clinical and laboratory features in the different groups are showed in Table 1. Regarding cardiovascular risk factors, SLE-APS patients had higher rates of hypertension, dyslipidemia and diabetes (p≤ 0.001). SLE-APS patients showed higher rates of neuropsychiatric, cardiac, pulmonary, renal and ophthalmological manifestations than the other groups (p< 0.001) (Table 1). In accordance with a more severe clinical profile, higher frequency of anti-DNA antibodies were observed in the SLE-APS group comparing with SLE (p< 0.001). SLE APS patients presented more damage accrual with higher values in SLICC (1.9±2.2 in SLE APS, 0.9±1.4 in SLE aPL and 1.1±1.6, p< 0.001) and Katz indexes (3±1.8 in SLE APS, 2.7±1.7 in SLE aPL and 2.6±1.6 in SLE no aPL, p < 0.001). In line with a more severe disease, mortality rate was higher in SLE APS patients (p< 0.001).
Conclusion: SLE-APS patients show a more severe clinical profile with higher frequency of major organ involvement and more damage accrual than SLE-aPL and SLE no APL
To cite this abstract in AMA style:Riancho-Zarrabeitia L, Martinez-Taboada V, Rua Figueroa I, Alonso F, Galindo M, Ovalles-Bonilla J, Olivé-Marqués A, Fernández-Nebro A, Calvo-Alen J, Menor Almagro R, Tomero-Muriel E, Uriarte Isacelaya E, Boteanu A, Andrés M, Freire González M, Santos Soler G, Ruiz Lucea E, Ibañez Barcelo M, Castellvi I, Galisteo C, Quevedo Vila V, Raya E, Narváez J, Expósito L, Hernández-Beriain J, Horcada Rubio L, Aurrecoechea E, Pego-Reigosa J. Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/antiphospholipid-syndrome-aps-in-systemic-lupus-erythematosus-sle-leads-to-a-more-severe-disease/. Accessed December 4, 2020.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-syndrome-aps-in-systemic-lupus-erythematosus-sle-leads-to-a-more-severe-disease/